International differences in clinical characteristics, management, and outcomes in acute heart failure patients: Better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial

European Journal of Heart Failure

Volumn 16, Issue 6, 2014, Pages 614-624

  Mentz, Robert J ^a   Cotter, Gad ^b   Cleland, John G F ^c   Stevens, Susanna R ^d   Chiswell, Karen ^d   Davison, Beth A ^b   Teerlink, John R ^e   Metra, Marco ^f   Voors, Adriaan A ^g   Grinfeld, Liliana ^h   Ruda, Mikhail ⁱ   Mareev, Viacheslav ^j   Lotan, Chaim ^k   Bloomfield, Daniel M ^l   Fiuzat, Mona ^a   Givertz, Michael M ^m   Ponikowski, Piotr ⁿ   Massie, Barry M ^e   O'Connor, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Momentum Research Inc   (United States)

^c UNIVERSITY OF HULL   (United Kingdom)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF BRESCIA   (Italy)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

^h UNIVERSIDAD DE BUENOS AIRES   (Argentina)

ⁱ INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^j Myasnikow Institute of Cardiology   (Russian Federation)

^k HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^l MERCK RESEARCH LABORATORIES   (United States)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁿ WROCLAW MEDICAL UNIVERSITY   (Poland)

more..

Author keywords

Acute heart failure; Global variation; Length of stay; Outcomes; Regional differences; Trial

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NITRIC ACID DERIVATIVE; PLACEBO; ROLOFYLLINE; VASODILATOR AGENT; ADENOSINE A1 RECEPTOR ANTAGONIST; XANTHINE DERIVATIVE;

ACUTE HEART FAILURE; ADULT; AGED; ARGENTINA; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CLINICAL FEATURE; EASTERN EUROPE; FEMALE; GEOGRAPHICAL VARIATION (SPECIES); HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; ISRAEL; KIDNEY DYSFUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RUSSIAN FEDERATION; WESTERN EUROPE; ACUTE DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; GEOGRAPHY; HEART FAILURE; INTERNATIONAL COOPERATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ACUTE DISEASE; ADENOSINE A1 RECEPTOR ANTAGONISTS; AGED; AGED, 80 AND OVER; DIURETICS; EUROPE, EASTERN; FEMALE; GEOGRAPHY; HEART FAILURE; HOSPITALIZATION; HUMANS; INTERNATIONALITY; LENGTH OF STAY; MALE; MIDDLE AGED; QUALITY OF LIFE; RUSSIA; XANTHINES;

EID: 84901975364     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.92     Document Type: Article

References (26)

1. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA,. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009; 360: 816-823.
2. Mentz RJ, Kaski JC, Dan GA, Goldstein S, Stockbridge N, Alonso-Garcia A, Ruilope LM, Martinez FA, Zannad F, Pitt B, Fiuzat M, O'Connor CM,. Implications of geographical variation on clinical outcomes of cardiovascular trials. Am Heart J 2012; 164: 303-312.
3. Butler J, Subacius H, Vaduganathan M, Fonarow GC, Ambrosy AP, Konstam MA, Maggioni A, Mentz RJ, Swedberg K, Zannad F, Gheorghiade M,. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) Trial. J Am Coll Cardiol 2013; 61: 571-579.
4. Ohman EM, Roe MT,. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany 'Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified' (Thromb Haemost 2011; 105.5). Thromb Haemost 2011; 105: 763-765.
5. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K,. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54. (Pubitemid 27329022)
6. Massie BM, Cleland JG, Armstrong PW, Horowitz JD, Packer M, Poole-Wilson PA, Ryden L,. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Card Fail 1998; 4: 3-8. (Pubitemid 28252535)
7. Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M,. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol 2008; 52: 1640-1648.
8. Pitt B, Zannad F, Gheorghiade M, Martinez F, Love TE, Daniel C, Ahmed A,. Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial. Int J Cardiol 2010; 143: 309-316.
9. Bueno H, Ross JS, Wang Y, Chen J, Vidan MT, Normand SL, Curtis JP, Drye EE, Lichtman JH, Keenan PS, Kosiborod M, Krumholz HM,. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA 2010; 303: 2141-2147.
10. Eapen ZJ, Reed SD, Li Y, Kociol RD, Armstrong PW, Starling RC, McMurray JJ, Massie BM, Swedberg K, Ezekowitz JA, Fonarow GC, Teerlink JR, Metra M, Whellan DJ, O'Connor CM, Califf RM, Hernandez AF,. Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates? Findings from ASCEND-HF. Circ Heart Fail 2013; 6: 727-732.
11. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC,. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363: 1419-1428.
12. Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Mansoor GA, Bloomfield DM, Ponikowski P, O'Connor CM, Metra M, Massie BM,. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail 2010; 16: 25-35.
13. Kind P., The EuroQoL instrument: an index of health-related quality of life. In:, Spiker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996. p191- 201.
14. Dolan P,. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108. (Pubitemid 127453463)
15. Mentz RJ, Fiuzat M, Kraft M, Lindenfeld J, O'Connor CM,. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? J Card Fail 2012; 18: 413-422.
16. Mentz RJ, Fiuzat M, Wojdyla DM, Chiswell K, Gheorghiade M, Fonarow GC, O'Connor CM,. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. Eur J Heart Fail 2012; 14: 395-403.
17. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM,. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003. (Pubitemid 36315544)
18. Kociol RD, Lopes RD, Clare R, Thomas L, Mehta RH, Kaul P, Pieper KS, Hochman JS, Weaver WD, Armstrong PW, Granger CB, Patel MR,. International variation in and factors associated with hospital readmission after myocardial infarction. JAMA 2012; 307: 66-74.
19. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J,. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-463. (Pubitemid 36286187)
20. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J,. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464-474. (Pubitemid 36286188)
21. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Gattis-Stough W, Davis GW, Bristow MR,. Influence of global region on outcomes in heart failure beta-blocker trials. J Am Coll Cardiol 2011; 58: 915-922.
22. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JG, Metra M, Aban IB, Greene SJ, Adams KF, McMurray JJ, Ahmed A,. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 2013; 15: 551-559.
23. Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, Douglas Kirk J, Miller CD, Nowak R, Frank Peacock W, Tavares M, Mebazaa A, Gheorghiade M,. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail 2010; 12: 1253-1260.
24. Krumholz HM, Lin Z, Keenan PS, Chen J, Ross JS, Drye EE, Bernheim SM, Wang Y, Bradley EH, Han LF, Normand SL,. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA 2013; 309: 587-593.
25. Heidenreich PA, Sahay A, Kapoor JR, Pham MX, Massie B,. Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs health care system 2002 to 2006. J Am Coll Cardiol 2010; 56: 362-368.
26. Kociol RD, Liang L, Hernandez AF, Curtis LH, Heidenreich PA, Yancy CW, Fonarow GC, Peterson ED,. Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. Am Heart J 2013; 165: 987-994.e1.